Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 2Thoracic 1Other hematologic neoplasm 1Myeloid 1Genitourinary 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 335Pemetrexed 276Cisplatin 228Paclitaxel 193pembrolizumab 178Erlotinib Hydrochloride 173Docetaxel 154Gemcitabine 126Nivolumab 112Bevacizumab 112Radiotherapy 84Etoposide 68durvalumab 62atezolizumab 59Ipilimumab 51Radiosurgery 49osimertinib 42130-nm albumin-bound paclitaxel 40Afatinib 39Gefitinib 38Cetuximab 38Albumin-Bound Paclitaxel 37Taxes 32Vinorelbine 29Radiation 29Topotecan 28Drug Therapy 25Crizotinib 23Platinum 21Dexamethasone 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Digoxin × Thoracic × Clear all
NCT00281021 2018-03-29

Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer

University of Louisville

Phase 2 Terminated
26 enrolled 5 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡